Prostate cancer: trends in mortality and stage-specific incidence rates by racial/ethnic group in Los Angeles County, California (United States)
Received: 08 May 1995 Accepted: 14 August 1995 DOI:
10.1007/BF00054156 Cite this article as: Danley, K.L., Richardson, J.L., Bernstein, L. et al. Cancer Causes Control (1995) 6: 492. doi:10.1007/BF00054156
Between 1976 and 1988 in the United States, the secular trends in age-adjusted incidence rates of prostate cancer were significantly different by racial/ethnic group (
P<0.001), and increased significantly only among non-Hispanic Whites at a rate of 2.7 percent (95 percent confidence interval [CI]=2.3–3.1%) annually. While incidence rates of regional disease increased significantly (7.7 percent to 11.3 percent annually) among all racial/ethnic groups during this period, localized disease increased significantly only among non-Hispanic Whites, by 1.8 percent (CI=1.4–2.3%) annually. Prostate cancer mortality in Los Angeles County (California) remained constant among Hispanics, non-Hispanic Whites, and Asians, but increased 1.6 percent (CI=0–3.2%) annually among Blacks. While the increase in localized disease rates of non-Hispanic Whites may be due to increased detection of asymptomatic disease, this apparently has not occurred among other racial/ethnic groups in Los Angeles County. The secular increase in regional disease rates among all racial/ethnic groups without a concurrent increase in mortality (except Blacks), suggests increased accuracy of staging rather than a true increase in incidence may account for these trends. Adjusted for socioeconomic status, year and age at diagnosis, Black and Hispanic men were at significantly higher risk of being diagnosed with non-localized disease (odds ratio = 1.39 and 1.24, respectively) than were non-Hispanic Whites. Key words Ethnicity males prostate cancer incidence prostate cancer mortality race United States
Drs Ross and Bernstein are also with the Cancer Surveillance Program
This work was supported in part by grant CA17054 from the US National Institutes of Health, and grant SIG#20 from the American Cancer Society. Cancer incidence data were collected under Subcontract 050H-8709 with the California Public Health Foundation. The subcontract is supported by the California Department of Health Services as part of its statewide cancer reporting program, mandated by Health and Safety Code Section 210 and 2113.
Chiarodo A. National Cancer Institute roundtable on prostate cancer: Future research directions.
National Cancer Institute.
Cancer Statistics Review 1973–1987
. Bethesda, MD (USA) Division of Cancer Prevention and Control, 1990; DHHS Pub. No. NIH 90–2789.
Muir CS, Nectous J, Staszewski J. The epidemiology of prostatic cancer. Geographic distribution and timetrends.
Department de Salud.
Cancer en Puerto Rico 1991
. San Juan, Puerto Rico: Department de Calud, 1993.
Lu-Yao GL, Greenberg ER. Changes in prostate cancer incidence and treatment in USA.
Waterhouse J, Muir C, Correa P, Powell J.
Cancer Incidence In Five Continents, Vol. III
. Lyon, France: International Agency for Research on Cancer, 1976; IARC Pub. No. 15.
Waterhouse J, Muir C, Shanmugaratnam K, Powell J.
Cancer Incidence in Five Continents, Vol, IV
. Lyon, France: International Agency for Research on Cancer, 1982; IARC Sci. Pub. No. 42.
Muir C, Waterhouse J, Mack T, Powell J, Whelen S.
Cancer Incidence In Five Continents, Vol. V
. Lyon, France: International Agency for Research on Cancer, 1987; IARC Sci. Pub. No. 88.
Potosky AL, Kessler L, Gridley G, Brown CC, Horm JW. Rise in prostatic cancer incidence associated with increased use of transurethral resection.
Hanks GE, Myers CE, Scardino PT. Cancer of the prostate. In: De Vita VTJr, Hellman S, Rosenberg SA, eds.
Cancer: Principles and Practice of Oncology
. Philadelphia, PA (USA): J.B. Lippincott Co, 1993; 1073–108.
Gilliland FD, Becker TM, Key CR, Samet JM. Contrasting trends of prostate cancer incidence and mortality in New Mexico's Hispanics, non-Hispanic whites, American Indians, and blacks.
Natarajan N, Murphy GP, Mettlin C. Prostate cancer in Blacks: an update from the American College of Surgeons' Pattern of Care Studies.
J Surg Oncol
Levine MS, Arger PH, Coleman BG, Mulhern CBJr, Pollack HM, Wein AJ. Detecting lymphatic metastases from prostatic carcinoma: superiority of CT.
Am J Roentgen
Schaffer D, Pendergrass HP. Comparison of enzyme, clinical, radiographic, and radionuclide methods of detecting bone metastases from carcinoma of the prostate.
Murphy GP, Natarajan JE, Pontes JE, et al. The national survey of prostate cancer in the United States by the American College of Surgeons.
Thompson IM, Rounder JB, Teague JL, Peek M, Spence CR. Impact of routine screening for adenocarcinoma of the prostate on stage distribution.
Garnick MB. Prostate cancer: screening, diagnosis and management.
Ann Int Med
Polednak AP, Flannery JT. Black versus white racial differences in clinical stage at diagnosis and treatment of prostatic cancer in Connecticut.
Austin JP, Aziz H, Potters L, et al. Diminished survival of young blacks with adenocarcinoma of the prostate.
Am J Clin Oncol
Meikle AW, Smith JAJr, Epidemiology of prostate cancer.
Urol Clin N Amer
Mack TM. Cancer Surveillance Program in Los Angeles County.
Natl Cancer Inst Monogr
Hollingshead AB, Redlich FC.
Social Class and Mental Illness
. New York, NY (USA): Wiley, 1958.
Breslow NE, Day NE.
Statistical Methods in Cancer Research: Vol. II. The Design and Analysis of Cobort Studies
. Lyon, France: International Agency for Research on Cancer, 1987: IARC Sci. Pub. No. 82: 120–37.
Menck HR, Henderson BE, Pike MC, Mack T, Martin SP, SooHoo J. Cancer incidence in the Mexican-American
Sidney S, Quesenberry CPJr, Sadler MC, Guess HA, Lydick EG, Cattolica EV. Incidence of surgically treated benign prostatic hypertrophy and of prostate cancer among blacks and whites in a prepaid health care plan.
Am J Epidemiol
Google Scholar Copyright information
© Rapid Science Publishers 1995